## **Emgality (galcanezumab-gnlm) Prior Authorization Request Form**

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME	:	_ MEMBER'S FIRST	NAME:	
	view (e.g., chart notes or	lab data, to support tl	y. Attach any additional documentation ne authorization request). Information	
			☐ URGENT	
MEMBER INFORMATIO	N			
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRT	H:	
STREET ADDRESS:		,		
CITY:		STATE:	ZIP CODE:	
PATIENT INSURANCE	D NUMBER:			
☐ MALE ☐ FEMALE	HEIGHT (IN/CM):	_ WEIGHT (LB/KG)	: ALLERGIES:	
IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP  PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE):				
AUTHORIZED REPRESE	NTATIVE'S PHONE NUI	MBER:		
PRESCRIBER INFORM	ATION			
LAST NAME:		FIRST NAME:		
PRESCRIBER SPECIALTY:		EMAIL ADDRE	EMAIL ADDRESS:	
NPI NUMBER:		DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER:	FAX NUMBER:	
STREET ADDRESS:				
CITY:		STATE:	ZIP CODE:	
REQUESTER (if different than prescriber):		OFFICE CONT	OFFICE CONTACT PERSON:	
		,		
MEDICATION OR MEDI	CAL DISPENSING INFO	RMATION		
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REF	QUANTITY:	
☐ NEW THERAPY	RENEWAL IF		HERAPY INITIATED:	
DURATION OF THERAF	Y (SPECIFIC DATES):			
Continued on next page				

© 2024 Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management – Commercial Clients. Revision Date: 12.1.24 CAT009



## **Emgality (galcanezumab-gnlm)**

Prior Authorization Request Form
Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST N	AME:		
	OTHER MEDICATIONS FOR THIS	CONDITION?		
YES (if yes, complete below)				
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:		
2. LIST DIAGNOSES:		ICD-10:		
☐ Episodic migraine ☐ Chronic migraine ☐ Other diagnosis:	ICD-10 Code(s):			
<b>3. REQUIRED CLINICAL INFORMATION:</b> PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.				
Is patient going to be using drug in combination with a clinical trial?   Yes   No				
documentation. Is the prescriber a neurologist or Is the prescriber board certified in	diazepines)	he Medicine? □ Yes □ No		
Has the patient been evaluated for overuse headache due to triptans, ergot derivatives, opioid analgesics, non-opioid analgesics and combination products? $\ \square$ Yes $\ \square$ No				
presence of at least one of the fol AND/OR decreased migraine seve	on showing a positive clinical resp lowing since starting Aimovig: dec erity AND/OR improved daily functi	creased migraine frequency oning on the part of the patient.		
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?				

<sup>© 2024</sup> Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management – Commercial Clients. Revision Date: 12.1.24 **CAT009** 



## **Emgality (galcanezumab-gnlm) Prior Authorization Request Form**

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: MEMBE	R'S FIRST NAME:			
Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all				
required information is received.				
ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I				
understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and				
request the medical information necessary to verify the accuracy of the information reported on this form.				
Dragovikov Signatura ov Electronic I.D. Verification	Data			
Prescriber Signature or Electronic I.D. Verification:	Date:			
CONFIDENTIALITY NOTICE: The documents accompanyi	ng this transmission contain confidential health			
information that is legally privileged. If you are not the intend				
disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly				
prohibited. If you have received this information in error, ple	ase notify the sender immediately (via return			
FAX) and arrange for the return or destruction of these documents.				
EAV THIS FORM TO: 900 424 7640				

**FAX THIS FORM TO:** 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP-4201 P.O. Box 64811 St. Paul, MN 55164-0811 **Phone**: 877-228-7909

